Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
NCT ID: NCT00920816
Last Updated: 2022-05-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
492 participants
INTERVENTIONAL
2009-08-25
2021-04-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
NCT00678392
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
NCT00282048
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
NCT00835978
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)
NCT05941637
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
NCT02639182
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Axitinib (AG-013736)
axitinib will be given at a starting dose of 5 mg BID with continuous dosing
B
Sorafenib
sorafenib will be given at a dose of 400 mg BID continuous dosing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Axitinib (AG-013736)
axitinib will be given at a starting dose of 5 mg BID with continuous dosing
Sorafenib
sorafenib will be given at a dose of 400 mg BID continuous dosing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Evidence of measurable disease.
* Patients with mRCC must have received no prior systemic first-line therapy or must have progressive disease per RECIST (version 1.0) after one prior systemic first line regimen for metastatic disease containing sunitinib, cytokine(s), or both.
Exclusion Criteria
* Major surgery less that 4 weeks or radiation less than 2 weeks of starting study drug.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Advanced Medical Specialties
Miami, Florida, United States
Advanced Medical Specialties
Miami, Florida, United States
Illinois Cancer Specialists
Arlington Heights, Illinois, United States
Illinois Cancer Specialists
Niles, Illinois, United States
Indiana University Health Central Indiana Cancer Centers
Carmel, Indiana, United States
Indiana University Health Central Indiana Cancer Centers
Fishers, Indiana, United States
Indiana University Health Central Indiana Cancer Centers
Greenfield, Indiana, United States
Indiana University Health Central Indiana Cancer Centers
Indianapolis, Indiana, United States
Indiana University Health Central Indiana Cancer Centers
Indianapolis, Indiana, United States
Missouri Cancer Associates
Columbia, Missouri, United States
Nebraska Methodist Hospital
Omaha, Nebraska, United States
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, United States
US Oncology West Region
Henderson, Nevada, United States
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Hematology-Oncology Associates of Northern NJ, PA
Morristown, New Jersey, United States
Hematology-Oncology Associates of Northern NJ, PA
Parsippany, New Jersey, United States
New York Oncology Hematology, PC
Albany, New York, United States
New York Oncology Hematology, PC
Albany, New York, United States
New York Oncology Hematology, PC
Latham, New York, United States
New York Oncology Hematology, PC
Rexford, New York, United States
New York Oncology Hematology, PC
Troy, New York, United States
Raleigh Hematology Oncology Associates
Cary, North Carolina, United States
Raleigh Hematology Oncology Associates
Raleigh, North Carolina, United States
Raleigh Hematology Oncology Associates
Raleigh, North Carolina, United States
Northwest Cancer Specialists, PC
Portland, Oregon, United States
Northwest Cancer Specialists, PC
Portland, Oregon, United States
Northwest Cancer Specialists, PC
Portland, Oregon, United States
Northwest Cancer Specialists, PC
Tualatin, Oregon, United States
Penn State Milton S. Hershey Medical Center, Penn State Cancer Institute
Hershey, Pennsylvania, United States
Medical University of South Carolina University Hospital
Charleston, South Carolina, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Texas Oncology- Amarillo
Amarillo, Texas, United States
Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center
Beaumont, Texas, United States
Texas Oncology- Bedford
Bedford, Texas, United States
Texas Oncology- Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Texas Oncology- Fort Worth 12th Avenue
Fort Worth, Texas, United States
Texas Oncology- Southwest Fort Worth
Fort Worth, Texas, United States
Investigational Products Center (lPC)
Fort Worth, Texas, United States
US Oncology Research and Clinical Pharmacy
Fort Worth, Texas, United States
Texas Oncology - Grapevine
Grapevine, Texas, United States
Cancer Care Centers of South Texas
Kerrville, Texas, United States
Texas Oncology- McAllen South Second Street
McAllen, Texas, United States
Texas Oncology- Midland Allison Cancer Center
Midland, Texas, United States
Cancer Care Centers of South Texas
San Antonio, Texas, United States
Cancer Care Centers of South Texas
San Antonio, Texas, United States
Texas Oncology-Deke Slayton Cancer Center
Webster, Texas, United States
Texas Oncology-Weslaco
Weslaco, Texas, United States
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Christiansburg, Virginia, United States
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Low Moor, Virginia, United States
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Roanoke, Virginia, United States
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Salem, Virginia, United States
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Wytheville, Virginia, United States
Northwest Cancer Specialists, PC
Vancouver, Washington, United States
Northwest Cancer Specialists, PC
Vancouver, Washington, United States
Wenatchee Valley Medical Center
Wenatchee, Washington, United States
Clinic of Oncology
Banja Luka, , Bosnia and Herzegovina
Institute of Oncology, University Hospital Center Sarajevo
Sarajevo, , Bosnia and Herzegovina
University Clinical Center Tuzla, Clinic for Oncology, Hematology and Radiotherapy
Tuzla, , Bosnia and Herzegovina
Spetsializirana Bolnitsa za Aktivno Lechenie po Onkologiya, EAD, Klinika po Himioterapiya
Sofia, , Bulgaria
SBALOZ D-r Marko Markov-Varna
Varna, , Bulgaria
Instituto Clinico Oncologico del Sur
Temuco, Cautin, Chile
Instituto Clinico Oncologico del Sur
Temuco, Región de la AraucanÃa, Chile
Instituto de Terapias Oncologicas Providencia
Providencia, Santiago Metropolitan, Chile
Private Office
Santiago, , Chile
Cancer Institute and Hospital ,Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Chinese PLA General Hospital
Haidian District, Beijing Municipality, China
The Fuzhou General Hospital, PLA Nanjing Military Area Command
Fuzhou, Fujian, China
Urology Department, Sun Yet-Sen University Cancer Center
Guangzhou, Guangdong, China
Nanfang Hospital
Guangzhou, Guangdong, China
Nanjing Bayi Hospital
Nanjing, Jiangsu, China
The Oncology Department, Jiangsu Province Hospital
Nanjing, Jiangsu, China
Jilin Provincial Cancer Hospital
Changchun, Jilin, China
Urology Department, 1st Hospital of China Medical University
Shenyang, Liaoning, China
Xijing Hospital, The Fourth Military Medical University,Oncology Department
Xi'an, Shaanxi, China
Urology Department, Renji Hospital,Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology
Hangzhou, Zhejiang, China
Department of Urology,Peking University First Hospital
Beijing, , China
Beijing Cancer Hospital/Department of Renal Cancer and Melanoma
Beijing, , China
South-Western Hospital, 3rd Military Medical University
Chongqing, , China
Jiangsu Cancer Hospital
Nanjing, , China
Fudan University, Cancer Hospital, Department of Urology
Shanghai, , China
Tianjin Oncology Hospital,biology treatment department
Tianjin, , China
Urology Department, The Second Hospital of Tianjin Medical University
Tianjin, , China
BIBI General Hospital and Cancer Centre,
Hyderabad, Andhra Pradesh, India
Chinmaya Mission Hospital
Bangalore, Karnataka, India
Sri Venkateshwara Hospital
Bangalore, Karnataka, India
NU Hospitals
Bangalore, Karnataka, India
Cancer Care Clinic and Hospitals
Nagpur, Maharashtra, India
Shatabdi Superspeciality Hospital
Nashik, Maharashtra, India
Curie Manavata Cancer Centre
Nashik, Maharashtra, India
Deenanath Mangeshkar Hospital and Research Centre
Pune, Maharashtra, India
Sahyadri Speciality Hospital
Pune, Maharashtra, India
Shettys hospital
Bangalore, , India
University Malaya Medical Centre
Kuala Lumpur, , Malaysia
Hospital General de Mexico O.D.
Mexico City, Mexico City, Mexico
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Mexico City, Mexico City, Mexico
Centro Hemato-Oncologico Privado
Toluca, State of Mexico, Mexico
Centenario Hospital Miguel Hidalgo
Aguascalientes, , Mexico
Oaxaca Site Management Organization
Oaxaca City, , Mexico
Rm. 3227 Doctors Clinic, Annex II Bldg., National Kidney & Transplant Institute
Quezon City, Diliman, Philippines
St. Lukes Medical Center
Quezon City, National Capital Region, Philippines
University of the East Ramon Magsaysay Memorial Medical Center
Quezon City, National Capital Region, Philippines
Makati Medical Center
Makati City, , Philippines
Room 805, Committee on Research Room, Manila Doctors Hospital
Manila, , Philippines
Oncomed SRL
Timișoara, JUD. Timis, Romania
Institutul Oncologic "Prof.Dr.I.Chiricuta" Cluj-Napoca
Cluj-Napoca, , Romania
Institutul Oncologic ''Prof.Dr. I. Chiricuta'' Cluj Napoca
Cluj-Napoca, , Romania
GBU RO "Ryazan Regional Clinical Oncology Dispensary"
Ryazan, Russian Federation, Russia
FGBOU VO "Ryazan State Medical University named after academician I.P.Pavlov"
Ryazan, Russian Federation, Russia
Moscow State Healthcare Institution Oncology Clinical Dispensary #1
Moscow, , Russia
P.A. Herzen Moscow Oncology Research Institute,
Moscow, , Russia
FGBOU VO "First Saint-Petersburg State Medical University n.a. I.P.Pavlov"
Saint Petersburg, , Russia
Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic
Ufa, , Russia
GVI Oncology
Port Elizabeth, , South Africa
Taichung Veterans General Hospital
Taichung, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
KP Dnipropetrovska oblasna klinichna likarnia im. I.I. Mechnykova" Dnipropetrovskoi oblasnoi rady,
Dnipro, , Ukraine
Komunalne nekomertsiine pidpryiemstvo Kharkivskoi oblasnoi rady Oblasnyi medychnyi klinichnyi tsentr
Kharkiv, , Ukraine
DU Instytut Urolohii NAMN Ukrainy, viddil onkourolohii, KNP Kyivskyi miskyi klinichnyi onkolohichnyi
Kyiv, , Ukraine
Komunalne nekomertsiine pidpryiemstvo Lvivskoi oblasnoi rady Lvivskyi onkolohichnyi rehionalnyi
Lviv, , Ukraine
SI "Zaporizhzhya Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine"
Zaporizhzhya, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Rini BI, Atkins MB, Choueiri TK, Teresi RE, Rosbrook B, Thakur M, Hutson TE. Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinoma. Future Oncol. 2023 Dec;19(40):2623-2629. doi: 10.2217/fon-2023-0233. Epub 2023 Aug 1.
Aldin A, Besiroglu B, Adams A, Monsef I, Piechotta V, Tomlinson E, Hornbach C, Dressen N, Goldkuhle M, Maisch P, Dahm P, Heidenreich A, Skoetz N. First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 May 4;5(5):CD013798. doi: 10.1002/14651858.CD013798.pub2.
Rini BI, Atkins MB, Choueiri TK, Thomaidou D, Rosbrook B, Thakur M, Hutson TE. Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2021 Oct;19(5):e306-e312. doi: 10.1016/j.clgc.2021.03.019. Epub 2021 Apr 5.
de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.
Hutson TE, Al-Shukri S, Stus VP, Lipatov ON, Shparyk Y, Bair AH, Rosbrook B, Andrews GI, Vogelzang NJ. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Clin Genitourin Cancer. 2017 Feb;15(1):72-76. doi: 10.1016/j.clgc.2016.05.008. Epub 2016 May 27.
Grunwald V, Lin X, Kalanovic D, Simantov R. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26.
Qin S, Bi F, Jin J, Cheng Y, Guo J, Ren X, Huang Y, Tarazi J, Tang J, Chen C, Kim S, Ye D. Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. Onco Targets Ther. 2015 Jun 8;8:1363-73. doi: 10.2147/OTT.S83302. eCollection 2015.
Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH, Rosbrook B, Chen C, Kim S, Vogelzang NJ. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013 Dec;14(13):1287-94. doi: 10.1016/S1470-2045(13)70465-0. Epub 2013 Oct 25.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2010-018585-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
A4061051
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.